Skip to content

Foghorn Therapeutics Inc.

FHTX

CIK 0001822462

← back to feed
Revenue (TTM)
$24.93M
+36.8% YoY Q1 Apr 2026
Net Income (TTM)
−$72.49M
+14.2% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.12
+25.3% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-337.3%
Q1 Apr 2026
Net Margin
-290.8%
Q1 Apr 2026
Free Cash Flow (TTM)
−$110.52M
Q1 Apr 2026
Cash
$87.66M
Q1 Apr 2026
Total Debt
$0
Q1 Apr 2026
Shares Outstanding
58.71M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings